Is immediate postoperative intravesical chemotherapy beneficial in non-muscle-invasive bladder cancer?

BJU International

Volumn 105, Issue SUPPL. 2, 2010, Pages 14-17

  Ayres, Benjamin E ^a   Crew, Jeremy P ^b  

^a FRIMLEY PARK HOSPITAL   (United Kingdom)

^b NATIONAL HEALTH SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; MITOMYCIN C; PLACEBO; THIOTEPA;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; BLADDER IRRITATION; BLADDER SURGERY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; GENETIC ASSOCIATION; HUMAN; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SHORT SURVEY; SKIN ALLERGY; X CHROMOSOME;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 75149119311     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09152.x     Document Type: Short Survey

References (33)

1. Sylvester R, Oosterlinck W, van der Meijden A. A single postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage TaT1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004 171: 2186 2190
2. Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007 178: 2314 2330
3. Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder. Eur Urol 2008 54: 303 314
4. British Association of Urological Surgeons/British Uro-Oncology Group. MDT (Multidisciplinary Team). Guidance for Managing Bladder Cancer. BAUS/BUG, 2007. Available at: http://www.bauslibrary.co.uk/PDFS/BSONC/ MDT%20guidance%20for%20bladder%20cancer.pdf. Accessed November 2009
5. Berrum-Svennung I, Gransfors T, Jahnson S, Boman H, Holmang S. A single instillation of epirubicin after transurethral resection of bladder tumours prevents only small recurrences. J Urol 2008 179: 101 106
6. Gudjónsson S, Adell L, Merdasa F et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical monotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 2009 55: 773 780
7. Cai T, Nesi G, Tinacci G et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guérin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol 2008 180: 110 115
8. Sylvester RJ, van der Meijden APM, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients and seven EORTC trials. Eur Urol 2006 49: 466 477
9. Wilby D, Thomas K, Ray E, Chappell B, O'Brien T. Bladder cancer: new TUR techniques. World J Urol 2009 27: 309 312
10. Soloway MS, Jordan AM, Murphy WM. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. Prog Clin Biol Res 1989 310: 215 236
11. Page BH, Levison VB, Curwen MP. The site of recurrence of non-infiltrating bladder tumours. Br J Urol 1978 50: 237 242
12. Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 1980 46: 1158 1163
13. Hanus M, Matouskova M, Smolova H. Postoperative cytology in relation to recurrences of superficial bladder tumours. Int Urol Nephrol 1994 26: 655 660
14. Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001 165: 1121 1123
15. Höglund M. On the origin of syn-and metachronous urothelial carcinomas. Eur Urol 2007 51: 1185 1193
16. Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 2002 101: 1 6
17. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992 326: 737 740
18. Jones TD, Wang M, Eble JN et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005 11: 6512 6519
19. Brausi M, Collette L, Kurth K et al. EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002 41: 523 531
20. Miladi M, Peyromaure M, Zerbib M, Saïghi D, Debré B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003 43: 241 245
21. Mowatt G, N'Dow J, Zhu S et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy. Eur Urol Suppl 2009 8: 373
22. Pan JS, Slocum HK, Rustum YM, Greco WR, Gaeta JF, Huben RP. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. J Urol 1989 142: 1589 1593
23. Burnand KG, Boyd PJR, Mayo ME, Shuttleworth KED, Lloyd-Davies RW. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol 1976 48: 55 9
24. Bono AV, Hall RR, Denis L, Lovisolo JA, Sylvester R. Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. Eur Urol 1996 29: 385 390
25. Tolley DA, Parmar MK, Grigor KM et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow-up. J Urol 1996 155: 1233 1238
26. Kaasinen E, Rintala E, Hellström P et al. FinnBladder Group. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002 42: 167 174
27. American Urological Association. Guidelines on Management of Non-Muscle Invasive Bladder Cancer. AUA 2007 Annual Meeting; Anaheim, California
28. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006 175: 1641 1644
29. Mostafid AH, Rajkumar RGN, Stewart AB, Singh R. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. BJU Int 2006 97: 509 512
30. Bouffioux C, Kurth KH, Bono A et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol 1995 153: 934 941
31. Sylvester RJ, Oosterlinck W. An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: Has the evidence changed? Eur Urol 2009 56: 43 5
32. Hendricksen K, Witjes WPJ, Idema JG et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 2008 53: 984 991
33. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008 53: 709 719